KCTBASE

진행성 비소세포폐암의 표적치료 및 맞춤항암치료
Targeted therapy and tailored chemotherapy for advanced non-small cell lung cancer

대한내과학회지 2009년 77권 1호 p.9 ~ p.17

윤탁(Yun Tak) - 국립암센터 폐암센터/특수암센터 혈액종양클리닉

Abstract

The prognosis of advanced non-small cell lung cancer (NSCLC) is very poor and the median overall survival is 10 to 12 months, despite the use of chemotherapy and targeted therapy. Recently, many targeted agents for NSCLC have been developed and tested in clinical trials. Of these, chemotherapeutic agents targeting epidermal growth factor receptor (EGFR), such as gefitinib, erlotinib and cetuximab, have been very efficacious in the treatment of NSCLC. Many phase III trials have evaluated the efficacy of these agents in combination with cytotoxic chemotherapy. Based on the results of these trials, clinical and molecular predictors of the response to EGFR-targeted agents, such as EGFR mutations or gene amplification, have been elucidated. Recent advances in understanding the biologic basis of acquired resistance to these agents have potential to improve the clinical effectiveness of agents targeting EGFR. Another agent, bevacizumab, targets an angiogenesis inhibitor, and has improved the survival in advanced NSCLC when used in combination with chemotherapy. In addition, many agents targeting tyrosine kinase inhibitors are being used in clinical trials. This review summarizes the outcomes of clinical trials evaluating agents targeting EGFR, angiogenesis inhibitors, and other molecules used alone or in combination with chemotherapy for the treatment of advanced NSCLC. Also, the predictive role of NSCLC histology for chemotherapy response will be summarized from the results of phase III studies.

키워드

비소세포폐암, 분자표적치료, 상피세포성장수

Non-small cell lung cancer, Molecular targeted agents, Epidermal growth factor receptor, Angiogenesis inhibitor

KMID : 0882420090770010009

원문 및 링크아웃 정보

학회

등재저널 정보

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

estern and western comparision is required. 기존의 taxane, gemcitabine, platinum 등의 항암제는 조직학적유형에 따른 효과에 큰 차이가 없는 것으로 알려져고, pemetrexed경우 주로 비편평상피폐암에 효과적임.

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

KCD코드

ICD 03

건강보험코드

진행성 비소세포폐암의 표적치료 및 맞춤항암치료 Targeted therapy and tailored chemotherapy for advanced non-small cell lung cancer

Abstract

키워드

진행성 비소세포폐암의 표적치료 및 맞춤항암치료
Targeted therapy and tailored chemotherapy for advanced non-small cell lung cancer